Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment

CA Cancer Journal for Clinicians

Volumn 61, Issue 5, 2011, Pages 287-314

  Lewis, Mark A ^a   Hendrickson, Andrea Wahner ^a   Moynihan, Timothy J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCITONIN; CALCIUM; CISPLATIN; CONIVAPTAN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; DENOSUMAB; DIAZOXIDE; FUROSEMIDE; GALLIUM; GLUCAGON; GLUCONATE CALCIUM; HYDROCORTISONE; IFOSFAMIDE; IMATINIB; LOOP DIURETIC AGENT; MITHRAMYCIN; PAMIDRONIC ACID; PHOSPHATE; PIG INSULIN; PREDNISONE; RASBURICASE; SALBUTAMOL; STEROID; TOLVAPTAN; UNINDEXED DRUG; VINCA ALKALOID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AIRWAY OBSTRUCTION; ANAPHYLAXIS; CANCER PATIENT; CANCER SURVIVAL; CONTINUOUS INFUSION; EMERGENCY CARE; EXTRAVASATION; FEBRILE NEUTROPENIA; HEART TAMPONADE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPERVISCOSITY SYNDROME; HYPOCALCEMIA; HYPOGLYCEMIA; HYPONATREMIA; INTRACRANIAL HYPERTENSION; LEUKAPHERESIS; LEUKOSTASIS; LIVER DYSFUNCTION; MORBIDITY; MORTALITY; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PLASMAPHERESIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; SUPERIOR CAVA VEIN SYNDROME; TERMINAL DISEASE; TUMOR LYSIS SYNDROME; EMERGENCY; NEOPLASMS;

EMERGENCIES; HUMANS; NEOPLASMS;

EID: 80052328848     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20124     Document Type: Review

References (220)

1. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF,. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993; 71: 1309-1312. (Pubitemid 23054924)
2. Grill V, Martin TJ,. Hypercalcemia of malignancy. Rev Endocr Metab Disord. 2000; 1: 253-263.
3. Sargent JT, Smith OP,. Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol. 2010; 149: 465-477.
4. Stewart AF,. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352: 373-379.
5. Philbrick WM, Wysolmerski JJ, Galbraith S, et al. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev. 1996; 76: 127-173. (Pubitemid 26048280)
6. Deftos LJ,. Hypercalcemia in malignant and inflammatory diseases. Endocrinol Metab Clin North Am. 2002; 31: 141-158. (Pubitemid 34578618)
7. Nussbaum SR, Gaz RD, Arnold A,. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990; 323: 1324-1328. (Pubitemid 20364741)
8. Brizendine K, Wells JM, Flanders SA, Saint S, Centor RM,. Clinical problem-solving. In search ofâ∥ N Engl J Med. 2010; 363: 2249-2254.
9. Walji N, Chan AK, Peake DR,. Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J. 2008; 84: 418-427.
10. Evan AP, Coe FL, Lingeman JE, Worcester E,. Insights on the pathology of kidney stone formation. Urol Res. 2005; 33: 383-389. (Pubitemid 41752062)
11. Evenepoel P, Bammens B, Claes K, Kuypers D, Meijers BK, Vanrenterghem Y,. Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol. 2010; 5: 2085-2092.
12. Ladenson JH, Lewis JW, Boyd JC,. Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab. 1978; 46: 986-993. (Pubitemid 8358365)
13. Behl D, Hendrickson AW, Moynihan TJ,. Oncologic emergencies. Crit Care Clin. 2010; 26: 181-205.
14. Gurney H, Grill V, Martin TJ,. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993; 341: 1611-1613. (Pubitemid 23175243)
15. Mundy GR, Guise TA,. Hypercalcemia of malignancy. Am J Med. 1997; 103: 134-145. (Pubitemid 27352118)
16. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT,. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990; 112: 499-504. (Pubitemid 20100287)
17. Tanvetyanon T, Stiff PJ,. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006; 17: 897-907. (Pubitemid 43785797)
18. Kacprowicz RF, Lloyd JD,. Electrolyte complications of malignancy. Emerg Med Clin North Am. 2009; 27: 257-269.
19. Gralow JR,. Bisphosphonate risks and benefits: finding a balance. J Clin Oncol. 2010; 28: 4873-4876.
20. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007; 25: 2464-2472. (Pubitemid 46999218)
21. Wang CC, Chen YC, Shiang JC, Lin SH, Chu P, Wu CC,. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med. 2009; 27: 1174.e1-1174e.3.
22. Pelosof LC, Gerber DE,. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clinic Proc. 2010; 85: 838-854.
23. Davidson TG,. Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm. 2001; 58 (3 suppl): S8-S15. (Pubitemid 33062555)
24. Porcel SL, Cumplido JA, de la Hoz B, Cuevas M, Losada E,. Anaphylaxis to calcitonin. Allergol Immunopathol (Madr). 2000; 28: 243-245. (Pubitemid 30624787)
25. Warrell RP Jr, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS,. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med. 1988; 108: 669-674.
26. Spinazze S, Schrijvers D,. Metabolic emergencies. Crit Rev Oncol Hematol. 2006; 58: 79-89.
27. Fillastre JP, Canonne MA, Jeanne C, et al. Letter: Renal function and electrolyte disturbances in normocalcaemic and hypercalcaemic patients treated with mithramycin. Br J Cancer. 1974; 29: 490-491.
28. Green L, Donehower RC,. Hepatic toxicity of low doses of mithramycin in hypercalcemia. Cancer Treat Rep. 1984; 68: 1379-1381. (Pubitemid 15222020)
29. Roodman GD,. Mechanisms of bone metastasis. N Engl J Med. 2004; 350: 1655-1664.
30. Lewiecki EM, Miller PD, Leib ES, Bilezikian JP,. Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al. J Clin Densitom. 2005; 8: 143-144. (Pubitemid 41411242)
31. Lee RJ, Saylor PJ, Smith MR,. Treatment and prevention of bone complications from prostate cancer. Bone. 2011; 48: 88-95.
32. Lumachi F, Brunello A, Roma A, Basso U,. Cancer-induced hypercalcemia. Anticancer Res. 2009; 29: 1551-1555.
33. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology. 2005; 146: 3235-3243. (Pubitemid 41058092)
34. Freda BJ, Davidson MB, Hall PM,. Evaluation of hyponatremia: a little physiology goes a long way. Cleve Clin J Med. 2004; 71: 639-650. (Pubitemid 39193339)
35. Onitilo AA, Kio E, Doi SA,. Tumor-related hyponatremia. Clin Med Res. 2007; 5: 228-237. (Pubitemid 351731692)
36. Adrogue HJ,. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005; 25: 240-249. (Pubitemid 41202746)
37. Raftopoulos H,. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007; 15: 1341-1347. (Pubitemid 350077231)
38. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A,. Cisplatin-induced renal salt wasting syndrome. Southern Med J. 2010; 103: 793-799.
39. Jayachandran NV, Chandrasekhara PK, Thomas J, Agrawal S, Narsimulu G,. Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis. Rheumatology (Oxford). 2009; 48: 89-90.
40. Kirch C, Gachot B, Germann N, Blot F, Nitenberg G,. Recurrent ifosfamide-induced hyponatraemia. Eur J Cancer. 1997; 33: 2438-2439.
41. Ginsberg SJ, Comis RL, Fitzpatrick AV,. Vinblastine and inappropriate ADH secretion. N Engl J Med. 1977; 296: 941. (Pubitemid 8074098)
42. Stuart MJ, Cuaso C, Miller M, Oski FA,. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood. 1975; 45: 315-320.
43. Liapis K, Apostolidis J, Charitaki E, Panitsas F, Harhalakis N, Nikiforakis E,. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Ann Pharmacother. 2008; 42: 1882-1886.
44. Sherlock M, Thompson CJ,. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol. 2010; 162 (1 suppl): S13-S18.
45. Ellison DH, Berl T,. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007; 356: 2064-2072. (Pubitemid 46789896)
46. Beck LH,. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1979; 301: 528-530. (Pubitemid 9258261)
47. Reddy P, Mooradian AD,. Diagnosis and management of hyponatraemia in hospitalised patients. Int J Clin Pract. 2009; 63: 1494-1508.
48. Adrogue HJ, Madias NE,. Hyponatremia. N Engl J Med. 2000; 342: 1581-1589. (Pubitemid 30340505)
49. Ghali JK,. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology. 2008; 111: 147-157.
50. Ghali JK, Hamad B, Yasothan U, Kirkpatrick P,. Tolvaptan. Nat Rev Drug Discov. 2009; 8: 611-612.
51. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM,. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010; 25: 1524-1531.
52. McElroy MK, Lowy AM, Weidner N,. Case report: focal nesidioblastosis ("nesidioblastoma") in an adult. Hum Pathol. 2010; 41: 447-451.
53. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT,. The insulin-like growth factor system and sarcomas. J Pathol. 2009; 217: 469-482.
54. Bruzzone A, Varaldo M, Ferrarazzo C, Tunesi G, Mencoboni M,. Solitary fibrous tumor. Rare Tumors. 2010; 2: e64.
55. Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L,. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab. 1989; 68: 701-706. (Pubitemid 19088997)
56. Nauck MA, Reinecke M, Perren A, et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab. 2007; 92: 1600-1605. (Pubitemid 46997157)
57. Daughaday WH,. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I. J Clin Endocrinol Metab. 2007; 92: 1616. (Pubitemid 46997159)
58. Sillos EM, Shenep JL, Burghen GA, Pui CH, Behm FG, Sandlund JT,. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer. 2001; 92: 2237-2246. (Pubitemid 33029066)
59. Diaz J, Antoine J, Azad N,. A case of hypoglycemia, lactic acidosis, and hematologic malignancy. Endocr Pract. 2010; 16: 241-243.
60. de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007; 14: 979-993. (Pubitemid 351252430)
61. Habra MA, Nunez R, Chuang H, et al. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine. 2010; 37: 209-212.
62. Lam KY, Lo CY,. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf). 2002; 56: 95-101.
63. Tesfaye N, Seaquist ER,. Neuroendocrine responses to hypoglycemia. Ann N Y Acad Sci. 2010; 1212: 12-28.
64. Cryer PE,. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia. 2009; 52: 35-37.
65. van Bon AC, Benhadi N, Endert E, Fliers E, Wiersinga WM,. Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma. Neth J Med. 2009; 67: 274-278.
66. Teale JD, Wark G,. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf). 2004; 60: 457-460. (Pubitemid 38482508)
67. Arao T, Okada Y, Hirose A, Tanaka Y,. A rare case of adult-onset nesidioblastosis treated successfully with diazoxide. Endocr J. 2006; 53: 95-100.
68. Verschoor L, Wolffenbuttel BH, Weber RF,. Beta-blockade and carbohydrate metabolism: theoretical aspects and clinical implications. J Cardiovasc Pharmacol. 1986; 8 (11 suppl):S92-S95. (Pubitemid 17086493)
69. Thipaporn T, Bubpha P, Varaphon V,. Hepatocellular carcinoma with persistent hypoglycemia: successful treatment with corticosteroid and frequent high carbohydrate intake. J Med Assoc Thai. 2005; 88: 1941-1946. (Pubitemid 43275733)
70. Tufan A, Unal N, Koca E, Onal I, Aksu S, Haznedaroglu I,. Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome. Ann Hematol. 2006; 85: 183-184. (Pubitemid 43174274)
71. Gemici C,. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006; 18: 773-780. (Pubitemid 44645411)
72. Vogel P, Pletcher JM, Liang Y,. Spontaneous acute tumor lysis syndrome as a cause of early deaths in short-term carcinogenicity studies using p53 +/- mice. Vet Pathol. 2010; 47: 719-724.
73. Kallab AM, Jillella AP,. Tumor lysis syndrome in small cell lung cancer. Med Oncol. 2001; 18: 149-151. (Pubitemid 32929488)
74. Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB,. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer. 2001; 9: 554-557. (Pubitemid 32927888)
75. Sklarin NT, Markham M,. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 1995; 18: 71-73.
76. Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW,. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999; 85: 1055-1059. (Pubitemid 29115583)
77. van de Kerkhof JJ, Peters WG, Visser J, Creemers GJ,. Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med. 2001; 59: 83-85. (Pubitemid 32703744)
78. Malik IA, Abubakar S, Alam F, Khan A,. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. Southern Med J. 1994; 87: 409-411. (Pubitemid 24098297)
79. Noh GY, Choe DH, Kim CH, Lee JC,. Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. J Clin Oncol. 2008; 26: 6005-6006.
80. Hande KR, Garrow GC,. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993; 94: 133-139. (Pubitemid 23046437)
81. Cairo MS, Bishop M,. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127: 3-11. (Pubitemid 39331101)
82. Koduri PR,. Hyperphosphatemia and tumor lysis syndrome. Ann Hematol. 2005; 84: 696.
83. Cairo MS, Coiffier B, Reiter A, Younes A,. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010; 149: 578-586.
84. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol. 2010; 28: 4207-4213.
85. Ngugi NN, McLigeyo SO, Kayima JK,. Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East Afr Med J. 1997; 74: 503-509. (Pubitemid 127387168)
86. Allon M, Dunlay R, Copkney C,. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989; 110: 426-429. (Pubitemid 19088223)
87. Rashid A, Hamilton SR,. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol. 1997; 21: 60-69.
88. Rampello E, Fricia T, Malaguarnera M,. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006; 3: 438-447. (Pubitemid 44203816)
89. Reddy PS, Curtiss EI, O'Toole JD, Shaver JA,. Cardiac tamponade: hemodynamic observations in man. Circulation. 1978; 58: 265-272. (Pubitemid 8395931)
90. Spodick DH,. Acute cardiac tamponade. N Engl J Med. 2003; 349: 684-690. (Pubitemid 36976001)
91. Maisch B, Ristic A, Pankuweit S,. Evaluation and management of pericardial effusion in patients with neoplastic disease. Progress Cardiovasc Dis. 2010; 53: 157-163.
92. Bussani R, De-Giorgio F, Abbate A, Silvestri F,. Cardiac metastases. J Clin Pathol. 2007; 60: 27-34. (Pubitemid 46142668)
93. Patel J, Sheppard MN,. Primary malignant mesothelioma of the pericardium. Cardiovasc Pathol. 2011; 20: 107-109.
94. Colombo A, Olson HG, Egan J, Gardin JM,. Etiology and prognostic implications of a large pericardial effusion in men. Clin Cardiol. 1988; 11: 389-394.
95. Sternbach G,. Claude Beck: cardiac compression triads. J Emerg Med. 1988; 6: 417-419.
96. Jacob S, Sebastian JC, Cherian PK, Abraham A, John SK,. Pericardial effusion impending tamponade: a look beyond Beck's triad. Am J Emerg Med. 2009; 27: 216-219.
97. Shabetai R, Fowler NO, Fenton JC, Masangkay M,. Pulsus paradoxus. J Clin Invest. 1965; 44: 1882-1898.
98. Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clinic Proc. 2002; 77: 429-436. (Pubitemid 34465150)
99. Cooper JP, Oliver RM, Currie P, Walker JM, Swanton RH,. How do the clinical findings in patients with pericardial effusions influence the success of aspiration? Br Heart J. 1995; 73: 351-354.
100. Kim SH, Kwak MH, Park S, et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat. 2010; 42: 210-216.
101. Wagner PL, McAleer E, Stillwell E, et al. Pericardial effusions in the cancer population: prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thoracic Cardiovasc Surg. 2011; 141: 34-38.
102. Oida T, Mimatsu K, Kano H, et al. Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World J Gastroenterol. 2010; 16: 740-744.
103. Dequanter D, Lothaire P, Berghmans T, Sculier JP,. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 2008; 15: 3268-3271.
104. Ganeshan A, Hon LQ, Warakaulle DR, Morgan R, Uberoi R,. Superior vena caval stenting for SVC obstruction: current status. Eur J Radiol. 2009; 71: 343-349.
105. Schraufnagel DE, Hill R, Leech JA, Pare JA,. Superior vena caval obstruction. Is it a medical emergency? Am J Med. 1981; 70: 1169-1174. (Pubitemid 11072108)
106. Ahmann FR,. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984; 2: 961-969. (Pubitemid 14037777)
107. Wilson P, Bezjak A, Asch M, et al. The difficulties of a randomized study in superior vena caval obstruction. J Thorac Oncol. 2007; 2: 514-519. (Pubitemid 47171805)
108. Guijarro Escribano JF, Anton RF, Colmenarejo Rubio A, Saenz Cascos L, Sainz Gonzalez F, Alguacil Rodriguez R,. Superior vena cava syndrome with central venous catheter for chemotherapy treated successfully with fibrinolysis. Clin Transl Oncol. 2007; 9: 198-200.
109. Halfdanarson TR, Hogan WJ, Moynihan TJ,. Oncologic emergencies: diagnosis and treatment. Mayo Clinic Proc. 2006; 81: 835-848. (Pubitemid 43839500)
110. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011; 117: 1917-1927.
111. Zinner SH,. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999; 29: 490-494. (Pubitemid 29439940)
112. Kanamaru A, Tatsumi Y,. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004; 39 (1 suppl): S7-S10. (Pubitemid 38971469)
113. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730-751. (Pubitemid 34194843)
114. Bodey GP, Buckley M, Sathe YS, Freireich EJ,. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64: 328-340.
115. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J,. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004; 140: 18-25.
116. Schimpff SC,. Empiric antibiotic therapy for granulocytopenic patients. Bull N Y Acad Med. 1982; 58: 750-756. (Pubitemid 13182628)
117. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997; 24: 584-602. (Pubitemid 27143552)
118. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52: 427-431.
119. Raad I, Kassar R, Ghannam D, Chaftari AM, Hachem R, Jiang Y,. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis. 2009; 49: 1187-1194.
120. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-3205. (Pubitemid 46638957)
121. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47: 8-32.
122. Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 2001; 15: 203-207.
123. Bucholtz JD,. Metastatic epidural spinal cord compression. Semin Oncol Nurs. 1999; 15: 150-159.
124. Spiller WG,. Rapidly developing paraplegia associated with carcinoma. AMA Arch Neurol Psychiatry. 1925; 13: 471-478.
125. Abrahm JL, Banffy MB, Harris MB,. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life." JAMA. 2008; 299: 937-946. (Pubitemid 351397067)
126. Schiff D,. Spinal cord compression. Neurol Clin. 2003; 21: 67-86, viii. (Pubitemid 36169345)
127. Schiff D, O'Neill BP, Suman VJ,. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology. 1997; 49: 452-456. (Pubitemid 27368881)
128. Prasad D, Schiff D,. Malignant spinal-cord compression. Lancet Oncol. 2005; 6: 15-24. (Pubitemid 40089716)
129. Gilbert RW, Kim JH, Posner JB,. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978; 3: 40-51.
130. Cole JS, Patchell RA,. Metastatic epidural spinal cord compression. Lancet Neurol. 2008; 7: 459-466. (Pubitemid 351508481)
131. Kwok Y, Tibbs PA, Patchell RA,. Clinical approach to metastatic epidural spinal cord compression. Hematol Oncol Clin North Am. 2006; 20: 1297-1305. (Pubitemid 44739215)
132. Maranzano E, Latini P,. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995; 32: 959-967.
133. Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien). 1990; 107: 37-43.
134. Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining functional prognosis-prospective study. Radiology. 1990; 176: 279-282. (Pubitemid 20208150)
135. Martenson JA Jr, Evans RG, Lie MR, et al. Treatment outcome and complications in patients treated for malignant epidural spinal cord compression (SCC). J Neurooncol. 1985; 3: 77-84. (Pubitemid 15100188)
136. Deyo RA, Rainville J, Kent DL,. What can the history and physical examination tell us about low back pain? JAMA. 1992; 268: 760-765.
137. Li KC, Poon PY,. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. Magn Reson Imaging. 1988; 6: 547-556.
138. Yuh WT, Zachar CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR,. Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology. 1989; 172: 215-218. (Pubitemid 19192512)
139. van der Sande JJ, Kroger R, Boogerd W,. Multiple spinal epidural metastases; an unexpectedly frequent finding. J Neurol Neurosurg Psychiatry. 1990; 53: 1001-1003. (Pubitemid 20378906)
140. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH,. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994; 30A: 22-27. (Pubitemid 24058082)
141. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A,. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989; 39: 1255-1257. (Pubitemid 19239735)
142. Graham PH, Capp A, Delaney G, et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol). 2006; 18: 70-76. (Pubitemid 43056700)
143. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010; 35: E1221-E1229.
144. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005; 366: 643-648. (Pubitemid 41176016)
145. Ushio Y, Posner R, Posner JB, Shapiro WR,. Experimental spinal cord compression by epidural neoplasm. Neurology. 1977; 27: 422-429. (Pubitemid 8125718)
146. Rades D, Karstens JH, Hoskin PJ, et al. Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2007; 67: 525-531. (Pubitemid 46108325)
147. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005; 23: 3366-3375.
148. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC,. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007; 32: 193-199. (Pubitemid 46105806)
149. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008; 71: 484-490.
150. Moulding HD, Elder JB, Lis E, et al. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine. 2010; 13: 87-93.
151. Posner JB,. Management of brain metastases. Rev Neurol (Paris). 1992; 148: 477-487.
152. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE,. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22: 2865-2872. (Pubitemid 41079905)
153. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A,. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94: 2698-2705. (Pubitemid 34478086)
154. Patchell RA,. The management of brain metastases. Cancer Treat Rev. 2003; 29: 533-540. (Pubitemid 37428325)
155. Posner JB, Chernik NL,. Intracranial metastases from systemic cancer. Adv Neurol. 1978; 19: 579-592.
156. Wen PY, Black PM, Loeffler JS,. Treatment of metastatic cancer. In:, DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 2655-2670.
157. Tosoni A, Ermani M, Brandes AA,. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol. 2004; 52: 199-215. (Pubitemid 39593754)
158. Ay I, Francis JW, Brown RH Jr,. VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Res. 2008; 1234: 198-205.
159. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR,. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A. 2009; 106: 1977-1982.
160. Forsyth PA, Posner JB,. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993; 43: 1678-1683. (Pubitemid 23307934)
161. Nutt SH, Patchell RA,. Intracranial hemorrhage associated with primary and secondary tumors. Neurosurg Clin N Am. 1992; 3: 591-599.
162. Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr,. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 1991; 12: 293-300.
163. Schaefer PW, Budzik RF Jr, Gonzalez RG,. Imaging of cerebral metastases. Neurosurg Clin N Am. 1996; 7: 393-423. (Pubitemid 26246626)
164. Lee EL, Armstrong TS,. Increased intracranial pressure. Clin J Oncol Nurs. 2008; 12: 37-41.
165. Alberti E, Hartmann A, Schutz HJ, Schreckenberger F,. The effect of large doses of dexamethasone on the cerebrospinal fluid pressure in patients with supratentorial tumors. J Neurol. 1978; 217: 173-181. (Pubitemid 8278637)
166. Jarden JO, Dhawan V, Moeller JR, Strother SC, Rottenberg DA,. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol. 1989; 25: 239-245. (Pubitemid 19085514)
167. Galicich JH, French LA, Melby JC,. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. 1961; 81: 46-53.
168. Batchelor T, DeAngelis LM,. Medical management of cerebral metastases. Neurosurg Clin N Am. 1996; 7: 435-446. (Pubitemid 26246628)
169. Kim H, Lee JM, Park JS, et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun. 2008; 372: 243-248.
170. Peacock KH, Lesser GJ,. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 2006; 7: 479-489. (Pubitemid 44697785)
171. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS,. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clinic Proc. 2004; 79: 1489-1494. (Pubitemid 39578871)
172. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR,. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008 (2): CD004424.
173. Mullen EC, Wang M,. Recognizing hyperviscosity syndrome in patients with Waldenström macroglobulinemia. Clin J Oncol Nurs. 2007; 11: 87-95.
174. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000; 39: 1-18. (Pubitemid 30662024)
175. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995; 123: 656-664.
176. Buxbaum J,. Hyperviscosity syndrome in dysproteinemias. Am J Med Sci. 1972; 264: 123-126.
177. Menke MN, Feke GT, McMeel JW, Treon SP,. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenström's macroglobulinemia. Invest Ophthalmol Vis Sci. 2008; 49: 1157-1160.
178. Gertz MA, Fonseca R, Rajkumar SV,. Waldenström's macroglobulinemia. Oncologist. 2000; 5: 63-67.
179. Menke MN, Feke GT, McMeel JW, Branagan A, Hunter Z, Treon SP,. Hyperviscosity-related retinopathy in Waldenström macroglobulinemia. Arch Ophthalmol. 2006; 124: 1601-1606.
180. Vitolo U, Ferreri AJ, Montoto S,. Lymphoplasmacytic lymphoma- Waldenström's macroglobulinemia. Crit Rev Oncol Hematol. 2008; 67: 172-185.
181. Majhail NS, Lichtin AE,. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med. 2004; 71: 633-637. (Pubitemid 39193338)
182. Inaba H, Fan Y, Pounds S, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008; 113: 522-529.
183. Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M,. Leukocytoreduction for acute leukemia. Ther Apher. 2002; 6: 15-23. (Pubitemid 34218723)
184. Steinberg MH, Charm SE,. Effect of high concentrations of leukocytes on whole blood viscosity. Blood. 1971; 38: 299-301.
185. Harris AL,. Leukostasis associated with blood transfusion in acute myeloid leukaemia. Br Med J. 1978; 1: 1169-1171. (Pubitemid 8327491)
186. Chang MC, Chen TY, Tang JL, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007; 82: 976-980.
187. McLeod BC, Strauss RG, Ciavarella D, et al. Management of hematological disorders and cancer. J Clin Apher. 1993; 8: 211-230. (Pubitemid 23360777)
188. Grund FM, Armitage JO, Burns P,. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med. 1977; 137: 1246-1247. (Pubitemid 9067117)
189. Tryka AF, Godleski JJ, Fanta CH,. Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia. Cancer. 1982; 50: 2763-2770. (Pubitemid 13220782)
190. Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH,. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest. 2006; 130: 1803-1807. (Pubitemid 46033437)
191. Wood DE, Liu YH, Vallieres E, Karmy-Jones R, Mulligan MS,. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg. 2003; 76: 167-172; discussion 173-174.
192. Chen K, Varon J, Wenker OC,. Malignant airway obstruction: recognition and management. J Emerg Med. 1998; 16: 83-92. (Pubitemid 28087354)
193. Chen TF, Braidley PC, Shneerson JM, Wells FC,. Obstructing tracheal lipoma: management of a rare tumor. Ann Thorac Surg. 1990; 49: 137-139. (Pubitemid 20035139)
194. Mathisen DJ, Grillo HC,. Endoscopic relief of malignant airway obstruction. Ann Thorac Surg. 1989; 48: 469-473; discussion 473-475.
195. Wood D,. Airway stenting. Chest Surg Clin North Am. 2003; 13: 211-229.
196. Freitag L, Tekolf E, Steveling H, Donovan TJ, Stamatis G,. Management of malignant esophagotracheal fistulas with airway stenting and double stenting. Chest. 1996; 110: 1155-1160. (Pubitemid 26380465)
197. Cavaliere S, Venuta F, Foccoli P, Toninelli C, La Face B,. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest. 1996; 110: 1536-1542. (Pubitemid 26425156)
198. Han CC, Prasetyo D, Wright GM,. Endobronchial palliation using Nd:YAG laser is associated with improved survival when combined with multimodal adjuvant treatments. J Thorac Oncol. 2007; 2: 59-64. (Pubitemid 47163930)
199. Lemaire A, Burfeind WR, Toloza E, et al. Outcomes of tracheobronchial stents in patients with malignant airway disease. Ann Thorac Surg. 2005; 80: 434-437; discussion 437-438.
200. Chella A, Ambrogi MC, Ribechini A, et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer. 2000; 27: 169-175. (Pubitemid 30105656)
201. Suh JH, Dass KK, Pagliaccio L, et al. Endobronchial radiation therapy with or without neodymium yttrium aluminum garnet laser resection for managing malignant airway obstruction. Cancer. 1994; 73: 2583-2588. (Pubitemid 24155536)
202. Langer SW,. Extravasation of chemotherapy. Curr Oncol Rep. 2010; 12: 242-246.
203. Berghammer P, Pohnl R, Baur M, Dittrich C,. Docetaxel extravasation. Support Care Cancer. 2001; 9: 131-134. (Pubitemid 32246461)
204. Langer SW, Sehested M, Jensen PB,. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000; 6: 3680-3686.
205. Schulmeister L,. Preventing and managing vesicant chemotherapy extravasations. J Support Oncol. 2010; 8: 212-215.
206. Bertelli G,. Prevention and management of extravasation of cytotoxic drugs. Drug Saf. 1995; 12: 245-255.
207. Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum. 2009; 36: 651-658.
208. Wengstrom Y, Margulies A,. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008; 12: 357-361.
209. Dorr RT, Alberts DS,. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst. 1985; 74: 113-120. (Pubitemid 15173111)
210. Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007; 18: 546-550. (Pubitemid 46359637)
211. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006; 117: 391-397. (Pubitemid 43190153)
212. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005; 115: 584-591. (Pubitemid 40341714)
213. Brown SG,. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004; 114: 371-376. (Pubitemid 39119039)
214. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001; 61: 129-133. (Pubitemid 32786206)
215. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006; 103: 608-613. (Pubitemid 44602175)
216. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK,. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001; 82: 550-558. (Pubitemid 32826458)
217. Weiss RB,. Hypersensitivity reactions. Semin Oncol. 1992; 19: 458-477.
218. Szebeni J, Muggia FM, Alving CR,. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998; 90: 300-306. (Pubitemid 28182386)
219. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794-7803. (Pubitemid 46657376)
220. Millward MJ, Newell DR, Mummaneni V, et al. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer. 1995; 31A: 2409-2411. (Pubitemid 26050588)